CYTK supply chain intelligence for Cytokinetics, Incorporated: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Cytokinetics, Incorporated (CYTK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RPRX | Royalty Pharma plc | 92% | We have entered into certain revenue participation right purchase agreements for omecamtiv mecarbil, aficamten, and CK-586 with affiliates of Royalty Pharma, pursuant to which such affiliates purchas… |
| RPRX | Royalty Pharma plc | 92% | Reciprocal relationship from RPRX graph: Reciprocal relationship from CYTK graph: We have entered into certain revenue participation right purchase agreements for omecamtiv mecarbil, aficamten, and C… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC… |
| AZN | AstraZeneca PLC | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| BMY | Bristol-Myers Squibb Company | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulat… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regul… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from MRK grap… |
| MRK | Merck & Co., Inc. | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| NVSEF | Novartis AG | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CYTK graph: ty contract manufacturers for our… |
| SNYNF | Sanofi | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CUSTOMER-A | CUSTOMER-A | 90% | The following customers accounted for over 10% of total gross product revenue during the three months ended March 31, 2026. |
| CUSTOMER-B | CUSTOMER-B | 90% | The following customers accounted for over 10% of total gross product revenue during the three months ended March 31, 2026. |
| CUSTOMER-C | CUSTOMER-C | 90% | The following customers accounted for over 10% of total gross product revenue during the three months ended March 31, 2026. |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval o… |
| AZN | AstraZeneca PLC | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in… |
| MRK | Merck & Co., Inc. | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an … |
| NVSEF | Novartis AG | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval… |
| SNYNF | Sanofi | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from SNYN… |
| BAYER-AG | BAYER-AG | 62% | 2024 and $ 0.3 million as of December 31, 2023. Collaboration for Commercialization of Aficamten in Japan On November 19, 2024, we announced that we had entered into a collaboration and license agree… |
| BAYER-CONSUMER-CARE-AG | BAYER-CONSUMER-CARE-AG | 62% | 2024 and $ 0.3 million as of December 31, 2023. Collaboration for Commercialization of Aficamten in Japan On November 19, 2024, we announced that we had entered into a collaboration and license agree… |
| CO-INC-BAYER-AG-ASTRAZENECA-PLC | CO-INC-BAYER-AG-ASTRAZENECA-PLC | 62% | tient diagnosis data, prescriptions and treatment data, has identified approximately 10,000 treaters, which represent an estimated ~75% of HCM cardiologist patient volume, enabling us to design an ef… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | ult in the impairment of production and key business processes or loss of data or information. We are also potentially vulnerable to data security breaches—whether by employees or others—which may ex… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CYTK-DEBT | Debt stack $275.6M | 90% | Market cache reports total debt of $275.6M. |
| CYTK-DEBT-9003 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| CYTK-DEBT-9002 | Warrants outstanding: 23065 | 90% | xbrl warrant detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CYTK-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME | T. Rowe Price Investment Management, Inc. | 90% | 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 453 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 |